(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

PURPOSE: Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as (90)Y/(177)Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. Alternative treatments for patients with refractory disease are rare. Here we report the first-in-human experience with (213)Bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R., Murphy, K., Haberkorn, U., Morgenstern, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525192/
https://www.ncbi.nlm.nih.gov/pubmed/25070685
http://dx.doi.org/10.1007/s00259-014-2857-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525192/
https://www.ncbi.nlm.nih.gov/pubmed/25070685
http://dx.doi.org/10.1007/s00259-014-2857-9

Ejemplares similares